Changes in Epithelial Ovarian Cancer Recurrence and Survival According to Treatment Paradigm Shifts

Over two decades, with the advent of targeted therapies, complete cytoreduction (especially in PDS) has increased. Although the use of IDS also increased, residual disease (< 1 cm) after IDS was associated with poorer outcomes. While PFS remained unchanged, 5-year OS significantly improved among patients with advanced-stage disease diagnosed in the most recent period.